Syntrix Biosystems

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Syntrix Biosystems sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials 2 currently recruiting 6 completed early-phase tilt top decile by trial count

Syntrix Biosystems: 9 sponsored US clinical trials, 2 recruiting.

Syntrix Biosystems sponsors 9 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 6 completed. 0 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Melanoma Stage IV, with 1 trials.

Top-decile sponsor footprint

Syntrix Biosystems ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 2

Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer

NCT06228053
RECRUITING Phase 1

Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome

NCT04245397
ACTIVE NOT RECRUITING Phase 1

SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab

NCT03161431
COMPLETED Phase 1

A Randomized Study Investigating Oral Desmetramadol Dose Proportionality and Food Effect In Normal Human Subjects

NCT04683926
COMPLETED Phase 2

Omnitram Safety and Efficacy in the Treatment of Diabetic Neuropathy

NCT03664921
COMPLETED Phase 2

Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis

NCT03431974
COMPLETED Phase 1

Omnitram Pharmacokinetic and Analgesic Study Following CY2D6 Inhibition With Paroxetine In Healthy Volunteers

NCT03312777
COMPLETED Phase 1

Omnitram Pharmacokinetic Study In Healthy Volunteers

NCT02205554
COMPLETED Phase 1

Aminopterin Pharmacokinetic Study In Moderate to Severe Psoriasis

NCT00937027

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 3

Therapeutic Areas

Melanoma Stage IV 1
Melanoma Stage III 1
Pain 1
Myelodysplastic Syndromes 1
Metastatic Castration-Resistant Prostate Cancer 1

What is open in the Syntrix Biosystems pipeline

2 recruiting of 9 indexed (22% open); 6 completed (67%).

Phase mix: 0 late (III/IV) vs 9 early (I/II) (early-phase heavy).

Top condition: Melanoma Stage IV (1 trial), 4 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Syntrix Biosystems: open-pipeline peers nationwide

Peers matched on 9 registered trials and 22% open enrollment, not the therapeutic-area sidebar.

Syntrix Biosystems sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 8101214161820 0%10%20%30%40%50% Total trials Recruiting share Syntrix Biosystems4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi companyALX OncologyBiosense WebsterEnglewood Hospital and Medical CenterEnsysce Biosciences
Syntrix Biosystems sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Syntrix Biosystems sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 trials (± recruiting share)

Sponsors near 22% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Syntrix Biosystems page

9 registered trials is a research-attention snapshot, not an endorsement of Syntrix Biosystems or any single study.

  • 2 of Syntrix Biosystems's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Melanoma Stage IV is the condition Syntrix Biosystems studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Melanoma Stage IV trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Syntrix Biosystems pipeline card: 9 registered trials from official public datasets.Report a data error.